Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Krakow
Clinical trial register · Poland

Clinical Trials in Krakow, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 86 Poznan 43 Bydgoszcz 37 Krakow 36 Gdansk 27
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca70 Hoffmann-La Roche42 Eli Lilly and Company38 Merck Sharp & Dohme LLC36 Janssen Research & Development, LLC36 Clear sponsor filter
Site location
Warsaw86 Poznan43 Bydgoszcz37 Krakow36 Gdansk27
All 54 locations
Target enrolment
to

Trials with a site in Krakow

36 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
Krakow, Warsaw
2026-06-22
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Krakow, Warsaw, Gliwice, Katowice
2026-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Skórzewo, Krakow, Siedlce, Warsaw, Gliwice
2026-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Krakow, Wroclaw, Warsaw, Szczecin
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Skórzewo, Bydgoszcz, Krakow, Siedlce, Warsaw, Przemyśl, Koszalin
2025-11-26
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Bydgoszcz, Krakow, Wałbrzych, Warsaw, Bialystok, Słupsk, Olsztyn, Koszalin
2025-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Katowice
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Krakow, Lublin, Bialystok
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Skórzewo, Krakow, Nowy Sącz, Wałbrzych, Warsaw, Gdansk, Katowice
2025-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Poznan, Krakow, Warsaw, Koszalin
2025-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Bialystok, Gdynia
2025-03-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Poznan, Bydgoszcz, Krakow, Wroclaw, Warsaw, Gdynia, Bielsko-Biala, Katowice
2024-12-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Poznan, Włocławek, Krakow, Wroclaw, Lublin, Warsaw, Katowice, Szczecin
2024-11-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Poznan, Krakow, Wroclaw, Warsaw, Przemyśl, Gdansk, Olsztyn, Kielce
2024-10-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Krakow, Warsaw, Gdansk, Gliwice
2024-10-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Bydgoszcz, Krakow, Warsaw, Wieliszew, Bialystok, Gdynia, Gliwice, Szczecin
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bydgoszcz, Grudziądz, Gorlice, Krakow, Poznań, Lublin, Warsaw, Przemyśl
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Poznan, Bydgoszcz, Torun, Krakow, Nowy Targ, Oświęcim, Jelenia Góra, Wroclaw
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Gorlice, Krakow, Lublin, Warsaw, Przemyśl, Olsztyn
2024-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Poznan, Krakow, Lublin, Warsaw, Przemyśl, Bialystok, Gdansk, Prabuty
2024-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Bydgoszcz, Grudziądz, Torun, Krakow, Warsaw, Przemyśl, Olsztyn, Lodz
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Krakow, Lublin, Warsaw, Gdansk, Słupsk, Gliwice, Katowice, Olsztyn
2023-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Poznan, Bydgoszcz, Krakow, Warsaw, Przemyśl, Bialystok, Gdansk, Olsztyn
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Poznan, Torun, Krakow, Nowy Targ, Wadowice, Wroclaw, Warsaw, Chorzów
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Poznan, Bydgoszcz, Torun, Chrzanów, Krakow, Tarnów, Legnica, Lublin
2023-10-09
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Krakow, Lublin, Warsaw, Olsztyn, Lodz, Kielce
2022-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Krakow, Wałbrzych, Wroclaw, Lublin, Warsaw, Gdynia, Słupsk, Katowice
2022-01-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Przemyśl, Bialystok, Gliwice
2021-06-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Krakow, Otwock
2021-05-12
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Krakow, Wroclaw, Warsaw, Opole, Gdynia
2021-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Poznan, Bydgoszcz, Krakow, Warsaw
2021-02-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Krakow, Siedlce, Koszalin
2020-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Poznan, Torun, Krakow, Tarnów, Wroclaw, Siedlce, Warsaw, Przemyśl
2018-12-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Krakow, Warsaw, Gdynia, Gliwice, Lodz
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Poznan, Bydgoszcz, Krakow, Warsaw, Rzeszów, Gdansk, Bielsko-Biala, Katowice
2018-09-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Konin, Poznan, Bydgoszcz, Krakow, Warsaw, Opole, Bialystok, Gdansk
2018-08-21
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 October 2026. https://priyalifescience.com/clinical-trials-poland/city/krakow

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Krakow that also match the filters currently applied.

How many clinical trials are recruiting in Krakow?

23 of the 36 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Krakow), 36 studies
PhaseStudiesRecruitingShare
Phase 3261672.2%
Phase 26316.7%
Phase 1/2225.6%
Phase 2/3225.6%

Most active sponsors

Lead sponsors with the most studies (Krakow)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3623
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.